“…We read with interest the comments by Dr Pradhan concerning our article, in which we presented two cases of rapid cataractogenesis we believe were related to the trial drug rociletinib, also known as TIGER . Dr Pradhan commented on the history of development of the drug and mentioned some of the concerns that were held about its reported response success rate.…”